Hipromine SA
WSE:HPM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
182
278
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Hipromine SA
Cost of Revenue
Hipromine SA
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hipromine SA
WSE:HPM
|
Cost of Revenue
-zł4.5m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
W
|
Wawel SA
WSE:WWL
|
Cost of Revenue
-zł476.5m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-3%
|
|
|
T
|
Tarczynski SA
WSE:TAR
|
Cost of Revenue
-zł1.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-11%
|
|
|
Z
|
Zaklady Przemyslu Cukierniczego Otmuchow SA
WSE:OTM
|
Cost of Revenue
-zł225.6m
|
CAGR 3-Years
3%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
G
|
Gobarto SA
WSE:GOB
|
Cost of Revenue
-zł3.3B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-8%
|
|
|
M
|
Makarony Polskie SA
WSE:MAK
|
Cost of Revenue
-zł222.2m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-9%
|
|
Hipromine SA
Glance View
HiProMine SA engages in the provision of innovative technology for industrial scale of insect breeding and processing. The firm is engaged in production of protein products for pet food and fodder for fish farming based on industrial insects breeding. The company provides its products from production process to the final product.
See Also
What is Hipromine SA's Cost of Revenue?
Cost of Revenue
-4.5m
PLN
Based on the financial report for Dec 31, 2023, Hipromine SA's Cost of Revenue amounts to -4.5m PLN.
What is Hipromine SA's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-41%
Over the last year, the Cost of Revenue growth was -20%. The average annual Cost of Revenue growth rates for Hipromine SA have been -41% over the past three years .
You don't have any saved screeners yet